Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women - Findings from HPTN 084 Study DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure...

HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday’s decision by the...

HIV Prevention Trials Network Launches HPTN 094 (INTEGRA) Study Durham, N.C., June 09, 2021 (GLOBE NEWSWIRE) -- The HIV Prevention Trials Network (HPTN) announced today the launch of HPTN 094 (INTEGRA), a study to determine whether using mobile health units to...

HIV Prevention Trials Network Awarded U.S. National Institutes of Health Funding to Continue Research Agenda DURHAM, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Drs. Myron S. Cohen and Wafaa M. El-Sadr, principal investigators of the HIV Prevention Trials Network (HPTN), in collaboration with FHI 360, have...

Long-Acting Injectable Cabotegravir Is Highly Effective for the Prevention of HIV Infection in Cisgender Men and Transgender Women Who Have Sex With Men DURHAM, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- The HIV Prevention Trials Network (HPTN) announced today results from HPTN 083, a global randomized, controlled, double-blind study that compared the...